1. Home
  2. BCAL vs DRUG Comparison

BCAL vs DRUG Comparison

Compare BCAL & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern California Bancorp

BCAL

Southern California Bancorp

N/A

Current Price

$21.29

Market Cap

672.6M

Sector

Finance

ML Signal

N/A

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$78.83

Market Cap

778.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCAL
DRUG
Founded
2001
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
672.6M
778.4M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
BCAL
DRUG
Price
$21.29
$78.83
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$20.67
$129.25
AVG Volume (30 Days)
168.0K
176.6K
Earning Date
04-28-2026
05-15-2026
Dividend Yield
2.15%
N/A
EPS Growth
777.27
N/A
EPS
0.86
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.67
N/A
P/E Ratio
$24.65
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.87
$38.00
52 Week High
$22.00
$123.75

Technical Indicators

Market Signals
Indicator
BCAL
DRUG
Relative Strength Index (RSI) 52.79 51.33
Support Level $20.36 $76.54
Resistance Level $21.80 $83.65
Average True Range (ATR) 0.39 3.76
MACD -0.07 -0.07
Stochastic Oscillator 50.42 29.69

Price Performance

Historical Comparison
BCAL
DRUG

About BCAL Southern California Bancorp

California BanCorp is a relationship-focused community bank offering commercial loan and deposit products, along with other services delivered directly or through strategic alliances, to business and individual customers in its target markets. The Company provides financial products and services to individuals, professionals, and small to medium-sized businesses through its branch and commercial banking offices serving California. Its lending products consist mainly of construction and land development loans, real estate loans, C&I loans, and consumer loans, and it is a Preferred SBA Lender, while its deposit products consist mainly of demand deposit, money market, and certificates of deposit. The Company operates in one reportable segment, commercial banking.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: